LAVA Therapeutics N.V. (LVTX) Earnings History
Net Loss6 years of earnings data (2019–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
LAVA Therapeutics N.V. (LVTX) Earnings Overview
As of June 30, 2026, LAVA Therapeutics N.V. (LVTX) reported trailing twelve-month net income of -$23M, reflecting +40.1% year-over-year growth. The company earned $-0.87 per diluted share over the past four quarters, with a net profit margin of -209.6%.
Looking at the long-term picture, LVTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2019.
LAVA Therapeutics N.V. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), TGTX ($462M net income, 72.6% margin), FATE (-$130M net income, -2051.1% margin), LVTX has comparable earnings metrics. Compare LVTX vs IMVT →
LVTX Earnings vs Peers
Earnings metrics vs comparable public companies
LVTX Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$25M | +40.0% | -$30M | $-0.94 | -209.6% | -247.8% |
| 2023 | -$42M | -31.2% | -$43M | $-1.57 | -618.6% | -641.1% |
| 2022 | -$32M | +24.7% | -$35M | $-1.23 | -164.5% | -179.7% |
| 2021 | -$42M | -165.9% | -$44M | $-2.14 | -791.7% | -815.2% |
| 2020 | -$16M | -64.4% | -$15M | $-39.90 | -425.1% | -391.6% |
| 2019 | -$10M | - | -$10M | $-21.65 | - | - |
Download Data
Export LVTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LVTX — Frequently Asked Questions
Quick answers to the most common questions about buying LVTX stock.
What is LVTX earnings per share (EPS)?
LVTX trailing twelve-month (TTM) diluted EPS is $-0.87, reflecting +40.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2024 is available in the table on this page.
What is LAVA Therapeutics N.V.'s net income?
LAVA Therapeutics N.V. (LVTX) trailing twelve-month net income is $-23M as of 2024. Earnings grew +40.1% year-over-year.
Is LVTX profitable?
LVTX is not currently profitable on a TTM basis, reporting a net loss of $-23M. Net margin is -209.6%. Investors should monitor for a return to profitability.
What is LVTX's earnings growth rate?
LVTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2024.
What are LVTX's profit margins?
LAVA Therapeutics N.V. net profit margin is -209.6%, operating margin is -247.8%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -63.6%.
Is LVTX growing earnings?
Yes, LVTX earnings are accelerating — EPS growth of +40.1% exceeds the 5-year CAGR of N/A. TTM net income reached $-23M. Earnings momentum is strengthening.
What was LVTX's best earnings year?
LAVA Therapeutics N.V.'s highest annual net income on record is $-10M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2024 and includes all annual and quarterly figures.
What were LVTX's earnings last quarter?
LVTX's most recent reported quarter was Q3 2025. Net income was $-7M with diluted EPS of $-0.27. For a full breakdown of all quarters, see the quarterly earnings table on this page.